#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
Article Title: #ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12% Publication Date: February 9, 2026 According to a report on February 9, 2026, Roche delivered a thorough update regarding the late-stage trial of its…